MRI-Targeted Treatment
MRI-Targeted Treatment.
Up to 7x Reimbursement.At the Point of Care.
Promaxo demonstrated the precision and repeatability of MRI-Targeted therapies in an 18-month study — 100% of NanoKnife patients and 78% of cryoablation patients showed post-treatment PSA reduction. Brings targeted prostate treatment to the point of care for the first time.
01 · Targeted Treatment
Demonstrated accuracy with MRI-Targeted ablation.
18-month study of Promaxo MRI-Targeted ablation using NanoKnife (irreversible electroporation) and cryoablation therapies demonstrated reduction in post-treatment PSA. Unlike TRUS which offers soft tissue ablation only, Promaxo enables targeted treatment for prostate cancer.
NanoKnife patients
100%
Demonstrated post-treatment PSA reduction below baseline.
Cryoablation patients
78%
Demonstrated post-treatment PSA reduction below baseline.
Treatment reimbursement
Up to 7x
Improved reimbursements over standard of care.